Maegim한국어

티움바이오

321550KOSDAQSector: Pharma & Biotech
₩3,805 2.19%Market cap ₩114.3BAs of Jul 21, 2026 close · updated once daily
D
Grade D34.5 ptsTop 79% of 2,523 stocks
Financial strength
19.2
Growth momentum
70.7
Price attractiveness
26.0

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

19.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
161.1%
Below median · Top 88% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
110.8%
Below median · Top 73.4% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-131.4%
Below median · Top 77.6% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-49.8%
Below median · Top 84.3% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

70.7
How much did revenue grow in a year?
Revenue growth (YoY)
80.9%
Above median · Top 10.3% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
10.5%
Above median · Top 31.6% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
13.7%
Above median · Top 42.2% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
37.0%
Above median · Top 33.1% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

26.0
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 79.9% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
2.80x
Below median · Top 68.1% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15